AAN 2021 | Updates on the INTREPID trial: 4-year follow-up
Jerrold Vitek, MD, PhD University of Minnesota, Minneapolis, MN, discusses the 4-year follow-up analysis of the INTREPID trial (NCT01839396). This trial evaluated the safety and effectiveness of a novel Deep Brain Stimulation (DBS) device capable of Multiple Independent Current Control (MICC) in the treatment of patients with advanced, levodopa-responsive bilateral Parkinson’s disease (PD), which is not adequately controlled with medication. This interview took place during the American Academy of Neurology (AAN) 2021 Annual Meeting.
Disclosures
Dr. Vitek has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Boston Scientific, Abbott, and Surgical Information Sciences. Dr. Vitek has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medtronic. Dr. Vitek has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Surgical Information Sciences. Dr. Vitek has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbott. Dr. Vitek has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Boston Scientific. The institution of Dr. Vitek has received research support from NINDS.
